Roivant 2Q 2026 Earnings Call - ROIVANT SCIENCES LTD

Explicit Guidance:

• None provided; management explicitly stated they are not providing specific financial guidance at this time due to the early stage of the Lysriah launch and ongoing FDA discussions.

Business-Segment Outlook:

• Lysriah (Dermatomyositis): Commercial launch began in August 2026; currently five weeks on market. Revenue of $31M reflects strong initial demand with hundreds of patients on paid drug by quarter-end, rising to "many hundreds" by early November. Expect strong uptick in September, potential modest headwind in Q4 2026 due to inventory clearing, with inventory dynamics expected to become irrelevant heading into 2027.
• IMVG-1402 (Rheumatoid Arthritis): Phase 2b Period 2 data met primary endpoint (ACR20 maintenance) with 92.5% of patients maintaining response at Week 28 vs 75% on placebo. 600mg dose confirmed necessary for efficacy vs 300mg. FDA discussions ongoing; final trial design (likely parallel RCT vs. randomized withdrawal) and regulatory path expected to be finalized later this year or early next year.
• Brepo (Brepocitinib): Phase 3 study for Nephrotic Immune Uveitis (NIU) data met all endpoints; pursuing NDA filing in 2027. Expect indication expansion for NIU and potential new indications in the near term.
• Moseley-Sigawatt (Trevo-1): Phase 3 study for Pulmonary Hypertension with Idiopathic Lung Disease (PHILD) is actively enrolling. Additional Phase 2/3 programs targeting other pulmonary hypertension indications (PAH, IPF, PPF) and other pulmonary diseases are in development; specific starts and indications to be determined.
• Graves' Disease and Myasthenia Gravis (MG): Enrollment described as "strong" for Graves' studies (26 weeks long). Expect timing updates and enrollment details in the "relatively near future" (likely prior to or at next earnings cycle).

Market and Competitive Outlook:

• Lysriah: Addressing high unmet need in dermatomyositis; broad initial prescriber base including specialists switching from off-label JAK inhibitors and IVIG, as well as newly diagnosed patients. Payer dynamics initially straightforward with some national plans requiring prior systemic immunosuppressant trials; some plans have stricter controls, but management confident in navigating access.
• RA: Addressing ~85,000 late-line refractory RA patients in the U.S. who have failed TNFs, JAKs, and IL-6s. Competitive landscape highlighted by competitor (Martiva) safety failure, increasing urgency for effective therapies.
• NIU: Third leading cause of blindness; estimated 70,000–190,000 patients in posterior/intermediate/pan uveitis subgroups. BREPO data suggests potential new standard of care with steroid-free quiescence in ~66% of patients.
• PHILD: Estimated 200,000 patients in US/Europe with poor prognosis (1.5–2 year survival); no non-steroidal approved therapies currently. Moseley-Sigawatt data shows deepest PVR reduction (56% vs placebo) and functional improvement seen in a PHILD study.
• Pipeline Expansion: Aggressively exploring Moseley-Sigawatt in IPF and other pulmonary hypertension forms.

Macro / Industry Outlook:

• Regulatory: Active FDA engagement for RA (IMVG-1402) and NIU (Brepo) filings; management anticipates "aggressive" regulatory paths and "reasonable reactions" from FDA given data quality and high unmet need.
• Competitive Intelligence: Noting competitor J&J Sjogren's data showing dose-response issues and Amgen/Novartis FDA interactions, influencing internal decisions to pause Sjogren's progression.

Strategic Initiatives:

• NDA Filing: Submitting NDA for Brepo in NIU during 2027, with expectation of approval and subsequent indication expansions.
• M&A / Licensing / Partnerships: No specific M&A announced; focus remains on internal pipeline execution.
• Clinical Trial Execution: Initiating multiple Phase 3 studies for Moseley-Sigawatt in 2027; continuing RA Phase 3 planning pending FDA alignment; continuing Sjogren's Phase 2 to completion to extract learnings despite low probability of progression.
• Investor Relations: Upcoming Investor Day scheduled for December 9, 2026, to detail commercial opportunities for Lysriah, NIU, and pipeline expansion.
• Capital Allocation: Continued share repurchases; $280M repurchased (9.4M shares) in H1 2026. Cash balance at $4.2B as of Sept 30, 2026, bolstered by Moderna litigation proceeds.

Risks and Headwinds to Outlook:

• RA Regulatory Uncertainty: Specific trial design, endpoint selection, and Phase 3 necessity remain unconfirmed pending FDA discussions; potential for delays if agreement is not reached.
• Lysriah Payer Access: Future payer policies may become more restrictive than early launch conditions; potential for inventory headwinds in Q4 2026.
• Sjogren's Progression: Low likelihood of progressing Sjogren's program due to unfavorable futility analysis (failed in 500 patients) and competitor landscape; potential for wasted resources if re-evaluated.
• Competitive Dynamics: Potential entry of other therapies in RA and pulmonary indications could impact market share.
• Safety Signals: Monitoring for new safety signals, particularly in the context of FCRN inhibition across multiple indications.

Management Tone on the Future:

• High Confidence: Management described the quarter and year as "phenomenal," "transformational," and "tremendous."
• Optimism: Expresses strong belief in the depth of IgG suppression driving efficacy (RA), the commercial potential of Lysriah and NIU, and the breadth of the Moseley-Sigawatt program.
• Forward-Looking: 2027 is characterized as a "very busy year" with "hopeful surprises" expected.
• Transparency: Willing to disclose negative updates (Sjogren's, Phase 2b RA results) immediately to manage expectations and discuss next steps.

Miscellaneous:

• Revenue Recognition: Lysriah revenue ($31M) reflects sales to specialty pharmacies; significant undispensed inventory existed at Sept 30 but has since been dispensed.
• Clinical Data: RA Phase 2b data highlighted the necessity of high dose (600mg) over low dose (300mg) for sustained efficacy.
• Stock Performance: H1 2026 saw $280M in buybacks; cash position strong at $4.2B.
• Litigation: Proceeds from Moderna litigation contributed to cash reserves in the first half of 2026.